Arch Therapeutics Closes In On CE Mark For Novel Blood Control Agent
Executive Summary
Securing the CE mark for its topical hemostatic agent has taken Arch Therapeutics longer than expected, but the company now predicts filing for a CE mark by the end of 2016, and is looking for a partner to help commercialize it in Europe.